-
EP3505518
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3505518
| EP3505518 - POLYMORPHIC FORM OF AVIBACTAM SODIUM (NXL104) [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 10.12.2020 Database last updated on 15.06.2024 | |
| Former | Request for examination was made Status updated on 10.01.2020 | ||
| Former | The application has been published Status updated on 31.05.2019 | Most recent event Tooltip | 01.11.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Pfizer Ireland Pharmaceuticals Operations Support Group Ringaskiddy Cork / IE | [2021/21] |
| Former [2019/27] | For all designated states PFIZER IRELAND PHARMACEUTICALS Operations Support Group Ringaskiddy Cork / IE | Inventor(s) | 01 /
BHATTACHARYA, Sisir 558A New Highway Apt. 1H Hauppauge, NY 11788 / US | 02 /
BONNET, Alain 13 Impasse Forte-Maison Nogentel 02400 Chateau-Thierry / FR | 03 /
DEDHIYA, Mahendra G. 1 Lea Court Pomona, NY 10970 / US | 04 /
DUCANDAS, Véronique 141 Avenue Rouget de l'lsle 94400 Vitry Sur Seine / FR | 05 /
GIULIANI, Alexandre 13 Alleé des Tilleuls 94440 Villecresnes / FR | 06 /
PRIOUR, Alain 61 Bis Quai de la Seine 75019 Paris / FR | 07 /
RAVAUX, Valérie 816 Chemin de Veissieux Le Haut 01600 Reyrieux / FR | 08 /
SPARGO, Peter 22 Walmer Way Deal, Kent CT14 9QT / GB | [2019/27] | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2019/27] | Application number, filing date | 19151839.8 | 08.10.2010 | [2019/27] | Priority number, date | FR20090004864 | 09.10.2009 Original published format: FR 0904864 | US200926366309P | 23.11.2009 Original published format: US 26366309 P | [2019/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3505518 | Date: | 03.07.2019 | Language: | EN | [2019/27] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 27.03.2019 | Classification | IPC: | C07D471/08, A61K31/439, A61K31/551, A61P31/04 | [2019/27] | CPC: |
C07D471/08 (EP,CN,IL,KR,RU,US);
A61K31/4188 (RU);
A61K31/439 (IL,KR,RU,US);
A61K31/546 (IL);
A61K31/675 (IL,KR,US);
A61P31/04 (EP,IL,RU,US);
A61K2300/00 (IL);
C07B2200/07 (KR);
C07B2200/13 (CN,IL,KR,US);
Y02A50/30 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/07] |
| Former [2019/27] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | POLYMORPHE FORM VON AVIBACTAM SODIUM (NXL104) | [2019/27] | English: | POLYMORPHIC FORM OF AVIBACTAM SODIUM (NXL104) | [2019/27] | French: | FORME POLYMORPHE D'AVIBACTAM SODIUM (NXL104) | [2019/27] | Examination procedure | 29.11.2019 | Amendment by applicant (claims and/or description) | 03.01.2020 | Examination requested [2020/07] | 03.01.2020 | Date on which the examining division has become responsible | 09.12.2020 | Despatch of a communication from the examining division (Time limit: M04) | 07.04.2021 | Reply to a communication from the examining division | 25.05.2022 | Despatch of a communication from the examining division (Time limit: M02) | 31.05.2022 | Reply to a communication from the examining division | 22.12.2022 | Despatch of a communication from the examining division (Time limit: M04) | 21.02.2023 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP10762934.7 / EP2486038 | EP17182561.5 / EP3269717 | Fees paid | Renewal fee | 15.05.2019 | Renewal fee patent year 03 | 15.05.2019 | Renewal fee patent year 04 | 15.05.2019 | Renewal fee patent year 05 | 15.05.2019 | Renewal fee patent year 06 | 15.05.2019 | Renewal fee patent year 07 | 15.05.2019 | Renewal fee patent year 08 | 15.05.2019 | Renewal fee patent year 09 | 31.10.2019 | Renewal fee patent year 10 | 02.11.2020 | Renewal fee patent year 11 | 02.11.2021 | Renewal fee patent year 12 | 31.10.2022 | Renewal fee patent year 13 | 31.10.2023 | Renewal fee patent year 14 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [AD]WO0210172 (AVENTIS PHARMA SA [FR], et al) [AD] 1-9* abstract;; example 33c; claims 1, 7, 15 *; | [A] - LIVERMORE DAVID M. ET AL, "NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (2008), vol. 62, no. 5, pages 1053 - 1056, XP002582640 [A] 1-9 * the whole document * * figure 1 * DOI: http://dx.doi.org/10.1093/JAC/DKN320 | by applicant | WO0210172 | US6417175 | WO03063864 | US6906055 | US7419973 | FR2921060 |